BioCurie lands $1M state-backed seed round for AI cell therapy platform

What's the deal? BioCurieDealroom has a profile for this one. Try Dealroom → raised $1 million in seed capital in August 2026 through Delaware's Accelerator & Seed Capital Program, part of the State Small Business Credit InitiativeDealroom has a profile for this one. Try Dealroom → (SSBCI). The company is building an AI-driven digital platform for cell and gene therapy manufacturing.

What the money is for. Co-founder Irene RombelDealroom has a profile for this one. Try Dealroom → said the funding supported key hires and advances to the platform, helping the company secure its first major customer.

Why now? The programme is funded by $60.9 million awarded to Delaware by the US federal government in 2023. The Delaware Division of Small BusinessDealroom has a profile for this one. Try Dealroom → said the initiative has supported more than 60 ventures since 2024, including companies working in biotechnology and pharmaceuticals.

What it means. Delaware officials are positioning the programme as a way to build a stronger biotechnology and pharmaceutical ecosystem, with IncyteDealroom has a profile for this one. Try Dealroom → cited as an example of a company that grew from a local venture into a major employer.

Read more: Spotlight Delaware

Image credit: Generated with Gemini